STOCK TITAN

Roivant to Present at Targeted Protein Degradation Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Roivant Sciences (Nasdaq: ROIV) announced that CEO Matt Gline will present at Guggenheim’s Targeted Protein Degradation Day on March 16, 2022, at 1:15 p.m. ET. A live webcast will be accessible on the Roivant Investor Relations website. Roivant aims to enhance healthcare delivery by addressing inefficiencies and developing transformative medicines through its innovative Roivant platform. For updates, visit www.roivant.com.

Positive
  • None.
Negative
  • None.

BASEL, Switzerland and LONDON and NEW YORK and BOSTON, March 11, 2022 (GLOBE NEWSWIRE) -- Roivant Sciences (Nasdaq: ROIV) today announced that its CEO Matt Gline will present at Guggenheim’s Targeted Protein Degradation Day on Wednesday, March 16, 2022 at 1:15 p.m. ET.

A live webcast will be available under “Events & Presentations” on the Investors section of the Roivant website at https://investor.roivant.com/news-events/events.

About Roivant Sciences

Roivant's mission is to improve the delivery of healthcare to patients by treating every inefficiency as an opportunity. Roivant develops transformative medicines faster by building technologies and developing talent in creative ways, leveraging the Roivant platform to launch 'Vants' – nimble and focused biopharmaceutical and health technology companies. For more information, please visit www.roivant.com.

Roivant Sciences Forward-Looking Statements

This press release contains forward-looking statements. Statements in this press release may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), which are usually identified by the use of words such as "anticipate," "believe," "continue," "could," "estimate," "expect," "intends," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "would" and variations of such words or similar expressions. The words may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act.

Our forward-looking statements include, but are not limited to, statements regarding our or our management team's expectations, hopes, beliefs, intentions or strategies regarding the future, and statements that are not historical facts, including statements about the clinical and therapeutic potential of our product candidates, the availability and success of topline results from our ongoing clinical trials, any commercial potential of our product candidates and any pending or potential litigation, including but not limited to our expectations regarding the outcome of any such litigation and costs and expenses associated with such litigation. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements.

Although we believe that our plans, intentions, expectations and strategies as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a number of risks, uncertainties and assumptions, including, but not limited to, those risks set forth in the Risk Factors section of our filings with the U.S. Securities and Exchange Commission. Moreover, we operate in a very competitive and rapidly changing environment in which new risks emerge from time to time. These forward-looking statements are based upon the current expectations and beliefs of our management as of the date of this press release, and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as required by applicable law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts
Investors
Roivant Investor Relations
ir@roivant.com

Media
Paul Davis
Roivant Sciences
paul.davis@roivant.com


FAQ

When will Roivant Sciences CEO Matt Gline present at Guggenheim’s Targeted Protein Degradation Day?

Matt Gline will present on March 16, 2022, at 1:15 p.m. ET.

How can I watch the Roivant Sciences presentation at Guggenheim’s event?

The presentation can be viewed live on the Roivant Investor Relations website under 'Events & Presentations.'

What is the focus of Roivant Sciences as a company?

Roivant focuses on improving healthcare delivery by developing transformative medicines and technologies.

What ticker symbols are associated with Roivant Sciences?

The ticker symbols for Roivant Sciences are ROIV and ROIVW.

Where can I find more information about Roivant Sciences?

More information can be found on their official website at www.roivant.com.

Roivant Sciences Ltd. Common Shares

NASDAQ:ROIV

ROIV Rankings

ROIV Latest News

ROIV Stock Data

8.85B
503.26M
29.56%
79.44%
6.3%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
HAMILTON HM11